Lynparza Prescribing Information
deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1)].
Download Lynparza Prescribing Information
Information
Domain:
Source:
Link to this page:
Documents from same domain
Imfinzi Full Prescribing Information
den8dhaj6zs0e.cloudfront.netlung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (1.1) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). (1.2)
BREZTRI Full Prescribing Information
den8dhaj6zs0e.cloudfront.netIf the inhaler has not been used for more than 7 days, is dropped, or after weekly . cleaning, prime the inhaler again by releasing 2 sprays into the air away from the face, shaking well before each spray. 2.3 Dose counter. BREZTRI AEROSPHERE canister has an attached dose indicator, which indicates . how many inhalations remain.
SYMBICORT Medication Guide
den8dhaj6zs0e.cloudfront.netSYMBICORT comes in 2 strengths. Your healthcare provider has prescribed the strength that is best for you. Note the differences between SYMBICORT and your other inhaled medications, including the differences in prescribed use and physical appearance.
SYMBICORT Prescribing Information
den8dhaj6zs0e.cloudfront.net5.18 Hypokalemia and Hyperglycemia. 6 ADVERSE REACTIONS. 6.1 Clinical Trials Experience in Asthma 6.2 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease. 6.3 Postmarketing Experience. 7 DRUG INTERACTIONS. Antidepressants 7.3 Beta-Adrenergic Receptor Blocking Agents 7.4 Diuretics. 8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy …
US-56427 ---------------------------- DOSAGE AND ...
den8dhaj6zs0e.cloudfront.netnot start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG). (5.1, 6.1) • If: possible, manage bleeding without discontinuing ----- BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events. (5.4) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS IN PATIENTS WITH ACS ...
Farxiga Prescribing Information
den8dhaj6zs0e.cloudfront.netpatients with polycystic kidney disease or patients requiring or with a recent . history of immunosuppressive therapy for the treatment of kidney disease. FARXIGA is not expected to be effective in these populations. (1)----- DOSAGE AND ADMINISTRATION ----- • Assess volume status and correct volume depletion before initiating. ...
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE ...
den8dhaj6zs0e.cloudfront.netHealthcare Providers for detail on preparation and administration. (2) ... registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., anti-infectives).
CRESTOR PRESCRIBING INFORMATION
den8dhaj6zs0e.cloudfront.netreduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C (1.1) ... Monitor INR frequently until stable upon initiation or alteration of CRESTOR therapy. (5.4, 7.6) • Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥1 g/day)
Saphnelo full Prescribing Information
den8dhaj6zs0e.cloudfront.netwith severe active lupus nephritis or severe active central nervous system lupus. Use . of SAPHNELO is not recommended in these situations. (1)----- DOSAGE AND ADMINISTRATION -----The recommended dosage is 300 mg as an intravenous infusion over a 30-minute . …
CALQUENCE PRESCRIBING INFORMATION
den8dhaj6zs0e.cloudfront.netTable 1: Recommended Dose Modifications for Use with CYP3A Inhibitors or Inducers CYP3A Co-administered Drug Recommended CALQUENCE use Inhibition Strong CYP3A inhibitor Avoid concomitant use. If these inhibitors will be used short-term (such as anti-infectives for up to seven days), interrupt CALQUENCE. Moderate CYP3A inhibitor 100 mg once daily.
Related documents
ESSENTIAL WORKFORCE - California
covid19.ca.govthose who test and repair), personal protective equipment (PPE), isolation barriers, medical . ... 11. Donors of blood bone marrow, blood stem cell, or plasma and the workers of the organizations that operate and manage related activities. 12. Workers that manage health plans, billing, and health information. ...
Management of Rotator Cuff Injuries
www.aaos.orgACROMIOPLASTY & ROTATOR CUFF REPAIR Moderate strength evidence does not support the routine use of acromioplasty as a concomitant treatment as compared to arthroscopic repair alone for patients with small to medium sized full-thickness rotator cuff tears. Strength of Recommendation: Moderate
ASSEMBLY PROCESSES Welding FUNDAMENTALS OF WELDING
www.egr.msu.edu• Plasma Arc Welding (PAW) – a special form of GTAW but with a constricted plasma gas to attain a higher temperature • Carbon Arc Welding – Graphite is used as electrode • Stud Welding – for cookware, heat radiation fin. 15 2. Resistance Welding • RW – heat and pressure to accomplish coalescence. • Power source: heat generated:
Guideline: Primary postpartum haemorrhage
www.health.qld.gov.au• Repair—secure apex • Transfer to OT if unable to access site Thrombin • Do not wait for blood results to treat • Use ROTEM® /TEG® if available • Monitor 30–60 minutely FBC, ABG, coagulation profile, ionised calcium • Review MHP activation criteria • Avoid hypothermia and acidosis Unknown • Assess for: o Uterine rupture ...
Sears Protection Agreements
www.sears.comCRT-based or Plasma television burn-in, accidental damage, abuse, misuse, vandalism, theft, mold, mildew, rust or corrosion, animal or insect infestation, damage caused by lightning and other acts of nature such as hurricanes, tornadoes, floods, etc. d. Replacement of Covered Product will not be authorized for product mismatch; product upgrades;